IDO1 and gastrointestinal stromal tumor: In a mouse model of gastrointestinal stromal tumor (GIST), imatinib (a broad-spectrum TKI) was combined with an anti-CTLA-4 mAb to block T-cell immunosuppression mediated by indoleamine 2,3-dioxygenase (IDO).